載入...
Brodalumab in psoriasis: evidence to date and clinical potential
Brodalumab is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). Brodalumab is now licensed and approved for the treatment of moderate-to-severe chronic plaque psoriasis in North America and Europe. As the third to mark...
Na minha lista:
| 發表在: | Drugs Context |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioExcel Publishing Ltd
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6474429/ https://ncbi.nlm.nih.gov/pubmed/31024633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212570 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|